NCT05836324 is a Phase 1 clinical trial of INCA33890 in Solid Tumors, sponsored by Incyte Corporation.

Who is sponsoring NCT05836324?

NCT05836324 is sponsored by Incyte Corporation.

What drugs are being tested in NCT05836324?

Interventions in NCT05836324: INCA33890, bevacizumab, FOLFIRI, FOLFOX, Cetuximab.

What condition does NCT05836324 study?

NCT05836324 studies Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors.

Is NCT05836324 still recruiting?

NCT05836324 is currently recruiting now. Last updated 18 December 2025.

Last reviewed 2025-12-18 · How we verify

NCT05836324

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Recruiting now Phase 1 Last updated 18 December 2025

What this trial tests

Phase 1 trial testing INCA33890 in Solid Tumors in 408 participants. Currently enrolling.

Timeline

24 July 2023

Primary endpoint
13 January 2027

13 January 2027

Quick facts

Lead sponsor	Incyte Corporation
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	408
Start date	24 July 2023
Primary completion	13 January 2027
Estimated completion	13 January 2027
Sites	36 locations across Denmark, France, Japan, Italy, United Kingdom, Switzerland, United States, Spain

Drugs / interventions tested

INCA33890
bevacizumab (Bevacizumab-Bvzr) — full drug profile →
FOLFIRI (folfiri) — full drug profile →
FOLFOX (folfox) — full drug profile →
Cetuximab (cetuximab) — full drug profile →

Conditions studied

Solid Tumors — all drugs for Solid Tumors →
Advanced Solid Tumors — all drugs for Advanced Solid Tumors →
Metastatic Solid Tumors — all drugs for Metastatic Solid Tumors →

Sponsor

Incyte Corporation — full company profile →

Who can join

18 and older, any sex, with Solid Tumors or Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions.
Mandal K, Barik GK, Santra MK. · · 2025 · cited 10× · PMID 41057853 · DOI 10.1186/s12943-025-02400-z
A Comprehensive Exploration of Agents Targeting Tumor Microenvironment: Challenges and Future Perspectives.
Lopes CDH, Braganca Xavier C, Torrado C, Veneziani AC, et al · · 2024 · cited 5× · PMID 39524466 · DOI 10.36401/jipo-24-23

Verify or expand the search:

Other trials of INCA33890

Trials testing the same drug.

NCT07284849 — A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 i · Phase 3 · recruiting
NCT06179160 — A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation · Phase 1 · recruiting

Other recruiting trials for Solid Tumors

Currently open trials in the same condition.

NCT07529002 — Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors · recruiting
NCT07416123 — A Study of GEN1106 in Participants With Solid Tumors · Phase 1 · recruiting
NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
NCT07395258 — A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Differe · Phase 1 · recruiting
NCT07505069 — Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors · EARLY_PHASE1 · recruiting

Other Incyte Corporation trials

Trials by the same sponsor.

NCT07124078 — A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Di · Phase 2 · recruiting
NCT07441694 — Study of INCA036978 in Participants With Myeloproliferative Neoplasms · Phase 1 · recruiting
NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting
NCT07284849 — A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 i · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05836324 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Incyte Corporation
Last refreshed: 18 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05836324.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing